I see where you are coming from, but the pharmacy industry doesn't like speculation. Prove you can treat 4 or tell them you can treat 20.
To prove that 20 would take astrinomical funds and trails.
I don't work in a lab, but I get the feeling the indications picked, do also prove a broader range of treatments without actually saying so. But that's my speculation.
- Forums
- ASX - By Stock
- Ann: 2023 Results webinar
I see where you are coming from, but the pharmacy industry...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.86 |
Change
0.560(2.90%) |
Mkt cap ! $2.538B |
Open | High | Low | Value | Volume |
$19.80 | $20.00 | $19.40 | $3.777M | 191.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1060 | $19.83 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.87 | 209 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3 | 19.700 |
1 | 51 | 19.600 |
1 | 1500 | 19.540 |
2 | 2600 | 19.500 |
1 | 160 | 19.420 |
Price($) | Vol. | No. |
---|---|---|
19.700 | 28 | 1 |
19.900 | 180 | 1 |
19.910 | 255 | 2 |
19.970 | 2000 | 1 |
19.990 | 7618 | 2 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
CXO
Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered
NEU (ASX) Chart |